Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 524494 | NSE: IPCALAB

Ipca Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:43 pm

Market Cap 33,821 Cr.
Current Price 1,333
High / Low 1,758/1,052
Stock P/E46.1
Book Value 264
Dividend Yield0.30 %
ROCE12.8 %
ROE9.35 %
Face Value 1.00
PEG Ratio-5.40

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ipca Laboratories Ltd

Competitors of Ipca Laboratories Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Ipca Laboratories Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 1,4301,2891,5861,6011,5461,5121,5852,0342,0532,0332,0932,3552,245
Expenses 1,1231,0701,3171,3411,3301,3311,2781,6731,7221,7111,7001,9131,782
Operating Profit 308219269260216181308361331322393441463
OPM % 22%17%17%16%14%12%19%18%16%16%19%19%21%
Other Income 12152236313645-191-118212620
Interest 1379111831443329242317
Depreciation 5961626467706990100989910098
Profit before tax 26017022322316912925222528977290345368
Tax % 22%17%33%35%32%37%34%39%23%96%31%29%25%
Net Profit 198132145146110781641362211199246276
EPS in Rs 7.745.135.645.674.253.026.425.727.092.357.589.059.78

Last Updated: February 28, 2025, 7:11 pm

Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹2,245.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,355.00 Cr. (Sep 2024) to ₹2,245.00 Cr., marking a decrease of 110.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹1,782.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,913.00 Cr. (Sep 2024) to ₹1,782.00 Cr., marking a decrease of 131.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹463.00 Cr.. The value appears strong and on an upward trend. It has increased from 441.00 Cr. (Sep 2024) to ₹463.00 Cr., marking an increase of ₹22.00 Cr..
  • For OPM %, as of Dec 2024, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Sep 2024) to 21.00%, marking an increase of 2.00%.
  • For Other Income, as of Dec 2024, the value is ₹20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Sep 2024) to ₹20.00 Cr., marking a decrease of 6.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 23.00 Cr. (Sep 2024) to ₹17.00 Cr., marking a decrease of 6.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹98.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 100.00 Cr. (Sep 2024) to ₹98.00 Cr., marking a decrease of 2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹368.00 Cr.. The value appears strong and on an upward trend. It has increased from 345.00 Cr. (Sep 2024) to ₹368.00 Cr., marking an increase of ₹23.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Sep 2024) to 25.00%, marking a decrease of 4.00%.
  • For Net Profit, as of Dec 2024, the value is ₹276.00 Cr.. The value appears strong and on an upward trend. It has increased from 246.00 Cr. (Sep 2024) to ₹276.00 Cr., marking an increase of ₹30.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 9.78. The value appears strong and on an upward trend. It has increased from ₹9.05 (Sep 2024) to 9.78, marking an increase of ₹0.73.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:53 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 2,8133,2823,1442,8673,1563,2583,7464,6195,3955,7976,2047,6628,726
Expenses 2,2482,5392,6042,5732,7052,8033,0513,7153,8434,4725,2726,3387,107
Operating Profit 5657435412944514556959041,5521,3259321,3241,619
OPM % 20%23%17%10%14%14%19%20%29%23%15%17%19%
Other Income 1321322111415665595412317-51
Interest 363032352728222012114814193
Depreciation 87103180163173178182210209232262357396
Profit before tax 4546313611172622915467391,3891,1367458431,080
Tax % 29%24%28%18%26%18%19%18%17%20%34%37%
Net Profit 324479254931952394426041,141890479523723
EPS in Rs 12.8218.9610.073.697.719.4917.6023.9944.9434.8518.5821.5728.76
Dividend Payout % 16%13%5%0%6%5%9%10%9%11%22%19%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)47.84%-46.97%-63.39%109.68%22.56%84.94%36.65%88.91%-22.00%-46.18%9.19%
Change in YoY Net Profit Growth (%)0.00%-94.81%-16.41%173.06%-87.11%62.37%-48.29%52.26%-110.91%-24.18%55.37%

Ipca Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: December 14, 2024, 3:23 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 25252525252525252525252525
Reserves 1,5291,9342,1832,2342,4302,6633,0973,6024,6765,4395,8176,3076,675
Borrowings 6176039358677166284655012658071,4811,4381,202
Other Liabilities 5266486697657887999611,1301,0991,3491,3003,3263,521
Total Liabilities 2,6973,2113,8123,8923,9604,1164,5495,2586,0667,6228,62311,09711,424
Fixed Assets 1,1041,3541,8002,0141,9831,9531,9402,0592,0722,4022,7514,5544,523
CWIP 129165267129957366133235306140343485
Investments 99162613687120310505989626862944
Other Assets 1,4551,6831,7291,7231,7462,0032,4222,7563,2543,9245,1055,3395,472
Total Assets 2,6973,2113,8123,8923,9604,1164,5495,2586,0667,6228,62311,09711,424

Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹25.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹6,675.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6,307.00 Cr. (Mar 2024) to ₹6,675.00 Cr., marking an increase of 368.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹1,202.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹1,438.00 Cr. (Mar 2024) to ₹1,202.00 Cr., marking a decrease of 236.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹3,521.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹3,326.00 Cr. (Mar 2024) to ₹3,521.00 Cr., marking an increase of 195.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹11,424.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹11,097.00 Cr. (Mar 2024) to ₹11,424.00 Cr., marking an increase of 327.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹4,523.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹4,554.00 Cr. (Mar 2024) to ₹4,523.00 Cr., marking a decrease of 31.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹485.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹343.00 Cr. (Mar 2024) to ₹485.00 Cr., marking an increase of 142.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹944.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹862.00 Cr. (Mar 2024) to ₹944.00 Cr., marking an increase of 82.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹5,472.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹5,339.00 Cr. (Mar 2024) to ₹5,472.00 Cr., marking an increase of 133.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹11,424.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹11,097.00 Cr. (Mar 2024) to ₹11,424.00 Cr., marking an increase of 327.00 Cr..

Notably, the Reserves (₹6,675.00 Cr.) exceed the Borrowings (1,202.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-52.00140.00-394.00-573.00-265.00-173.00230.00403.00-264.00-806.00931.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days545041575867667155575880
Inventory Days247272293289290286316294337337276350
Days Payable891109714513013715413514010183110
Cash Conversion Cycle212213237200218216228229251293251321
Working Capital Days112981068494107109113119127119150
ROCE %24%28%14%5%9%10%16%19%31%20%11%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters46.29%46.29%46.29%46.29%46.29%46.29%46.29%46.29%46.30%46.30%46.30%44.72%
FIIs11.02%10.61%10.57%10.46%10.58%10.05%9.86%10.27%10.51%10.85%10.83%11.06%
DIIs32.70%33.49%33.46%33.71%33.74%34.86%34.72%34.19%34.05%33.46%33.90%35.36%
Government0.24%0.24%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%0.32%
Public9.75%9.37%9.34%9.22%9.06%8.46%8.80%8.93%8.82%9.07%8.64%8.53%
No. of Shareholders1,15,3351,10,8181,11,0431,08,1771,10,29699,88995,93082,80981,16584,75382,97590,189

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid-Cap Opportunities Fund - Regular Plan16,101,8932.581819.032,447,0562025-03-11558.01%
Kotak Emerging Equity Fund - Regular Plan9,174,3012.111036.422,447,0562025-03-11274.91%
DSP Mid Cap Fund5,164,7363.05583.462,447,0562025-03-11111.06%
Parag Parikh Flexi Cap Fund3,541,8310.56400.122,447,0562025-03-1144.74%
Nippon India Growth Fund3,100,0001.14350.212,447,0562025-03-1126.68%
DSP Small Cap Fund2,572,7271.91290.642,447,0562025-03-115.14%
HDFC Balanced Advantage Fund - Regular Plan2,447,0560.31276.442,447,0562025-03-110%
Kotak Equity Opportunities Fund - Regular Plan2,200,0001.03248.532,447,0562025-03-11-10.1%
DSP ELSS Tax Saver Fund1,681,0261.17189.912,447,0562025-03-11-31.3%
UTI Flexi Cap Fund1,645,5590.72185.92,447,0562025-03-11-32.75%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.002.002.00
Basic EPS (Rs.) 25.8218.5834.8545.0147.77
Diluted EPS (Rs.) 21.5718.5834.8545.0147.73
Cash EPS (Rs.) 34.9429.7045.07107.0665.05
Book Value[Excl.RevalReserv]/Share (Rs.) 304.57233.16219.51371.79288.18
Book Value[Incl.RevalReserv]/Share (Rs.) 304.57233.16219.51371.79288.18
Revenue From Operations / Share (Rs.) 303.71246.13229.79427.28367.92
PBDIT / Share (Rs.) 56.9941.4854.23126.7077.06
PBIT / Share (Rs.) 42.9131.1745.07110.2160.40
PBT / Share (Rs.) 33.2229.3844.77109.5059.10
Net Profit / Share (Rs.) 20.8619.3935.9190.5748.39
NP After MI And SOA / Share (Rs.) 21.5718.5834.8589.8747.99
PBDIT Margin (%) 18.7616.8523.5929.6520.94
PBIT Margin (%) 14.1212.6619.6125.7916.41
PBT Margin (%) 10.9311.9319.4825.6216.06
Net Profit Margin (%) 6.867.8715.6221.1913.15
NP After MI And SOA Margin (%) 7.107.5415.1621.0313.04
Return on Networth / Equity (%) 8.648.0616.0924.2416.71
Return on Capital Employeed (%) 12.4411.5918.5228.4819.40
Return On Assets (%) 4.935.4611.5718.7811.52
Long Term Debt / Equity (X) 0.090.110.070.000.02
Total Debt / Equity (X) 0.210.240.140.050.11
Asset Turnover Ratio (%) 0.780.760.790.910.89
Current Ratio (X) 2.352.873.042.962.15
Quick Ratio (X) 1.301.911.771.591.16
Inventory Turnover Ratio (X) 1.050.940.951.101.22
Dividend Payout Ratio (NP) (%) 9.2721.5311.478.9016.67
Dividend Payout Ratio (CP) (%) 5.6013.849.087.5212.37
Earning Retention Ratio (%) 90.7378.4788.5391.1083.33
Cash Earning Retention Ratio (%) 94.4086.1690.9292.4887.63
Interest Coverage Ratio (X) 10.4623.11178.91177.7959.01
Interest Coverage Ratio (Post Tax) (X) 5.6111.80119.46128.0838.05
Enterprise Value (Cr.) 33899.8720234.9027148.8824038.8217785.27
EV / Net Operating Revenue (X) 4.403.244.664.443.83
EV / EBITDA (X) 23.4519.2319.7314.9618.27
MarketCap / Net Operating Revenue (X) 4.083.294.624.453.77
Retention Ratios (%) 90.7278.4688.5291.0983.32
Price / BV (X) 4.963.524.905.134.83
Price / Net Operating Revenue (X) 4.083.294.624.453.77
EarningsYield 0.010.020.030.040.03

After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 25.82. This value is within the healthy range. It has increased from 18.58 (Mar 23) to 25.82, marking an increase of 7.24.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 21.57. This value is within the healthy range. It has increased from 18.58 (Mar 23) to 21.57, marking an increase of 2.99.
  • For Cash EPS (Rs.), as of Mar 24, the value is 34.94. This value is within the healthy range. It has increased from 29.70 (Mar 23) to 34.94, marking an increase of 5.24.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 304.57. It has increased from 233.16 (Mar 23) to 304.57, marking an increase of 71.41.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 304.57. It has increased from 233.16 (Mar 23) to 304.57, marking an increase of 71.41.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 303.71. It has increased from 246.13 (Mar 23) to 303.71, marking an increase of 57.58.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 56.99. This value is within the healthy range. It has increased from 41.48 (Mar 23) to 56.99, marking an increase of 15.51.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 42.91. This value is within the healthy range. It has increased from 31.17 (Mar 23) to 42.91, marking an increase of 11.74.
  • For PBT / Share (Rs.), as of Mar 24, the value is 33.22. This value is within the healthy range. It has increased from 29.38 (Mar 23) to 33.22, marking an increase of 3.84.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 20.86. This value is within the healthy range. It has increased from 19.39 (Mar 23) to 20.86, marking an increase of 1.47.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 21.57. This value is within the healthy range. It has increased from 18.58 (Mar 23) to 21.57, marking an increase of 2.99.
  • For PBDIT Margin (%), as of Mar 24, the value is 18.76. This value is within the healthy range. It has increased from 16.85 (Mar 23) to 18.76, marking an increase of 1.91.
  • For PBIT Margin (%), as of Mar 24, the value is 14.12. This value is within the healthy range. It has increased from 12.66 (Mar 23) to 14.12, marking an increase of 1.46.
  • For PBT Margin (%), as of Mar 24, the value is 10.93. This value is within the healthy range. It has decreased from 11.93 (Mar 23) to 10.93, marking a decrease of 1.00.
  • For Net Profit Margin (%), as of Mar 24, the value is 6.86. This value is within the healthy range. It has decreased from 7.87 (Mar 23) to 6.86, marking a decrease of 1.01.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 7.10. This value is below the healthy minimum of 8. It has decreased from 7.54 (Mar 23) to 7.10, marking a decrease of 0.44.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 8.64. This value is below the healthy minimum of 15. It has increased from 8.06 (Mar 23) to 8.64, marking an increase of 0.58.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 12.44. This value is within the healthy range. It has increased from 11.59 (Mar 23) to 12.44, marking an increase of 0.85.
  • For Return On Assets (%), as of Mar 24, the value is 4.93. This value is below the healthy minimum of 5. It has decreased from 5.46 (Mar 23) to 4.93, marking a decrease of 0.53.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 23) to 0.09, marking a decrease of 0.02.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.21. This value is within the healthy range. It has decreased from 0.24 (Mar 23) to 0.21, marking a decrease of 0.03.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.78. It has increased from 0.76 (Mar 23) to 0.78, marking an increase of 0.02.
  • For Current Ratio (X), as of Mar 24, the value is 2.35. This value is within the healthy range. It has decreased from 2.87 (Mar 23) to 2.35, marking a decrease of 0.52.
  • For Quick Ratio (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has decreased from 1.91 (Mar 23) to 1.30, marking a decrease of 0.61.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.05. This value is below the healthy minimum of 4. It has increased from 0.94 (Mar 23) to 1.05, marking an increase of 0.11.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 9.27. This value is below the healthy minimum of 20. It has decreased from 21.53 (Mar 23) to 9.27, marking a decrease of 12.26.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.60. This value is below the healthy minimum of 20. It has decreased from 13.84 (Mar 23) to 5.60, marking a decrease of 8.24.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 90.73. This value exceeds the healthy maximum of 70. It has increased from 78.47 (Mar 23) to 90.73, marking an increase of 12.26.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.40. This value exceeds the healthy maximum of 70. It has increased from 86.16 (Mar 23) to 94.40, marking an increase of 8.24.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 10.46. This value is within the healthy range. It has decreased from 23.11 (Mar 23) to 10.46, marking a decrease of 12.65.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.61. This value is within the healthy range. It has decreased from 11.80 (Mar 23) to 5.61, marking a decrease of 6.19.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 33,899.87. It has increased from 20,234.90 (Mar 23) to 33,899.87, marking an increase of 13,664.97.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.40. This value exceeds the healthy maximum of 3. It has increased from 3.24 (Mar 23) to 4.40, marking an increase of 1.16.
  • For EV / EBITDA (X), as of Mar 24, the value is 23.45. This value exceeds the healthy maximum of 15. It has increased from 19.23 (Mar 23) to 23.45, marking an increase of 4.22.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.29 (Mar 23) to 4.08, marking an increase of 0.79.
  • For Retention Ratios (%), as of Mar 24, the value is 90.72. This value exceeds the healthy maximum of 70. It has increased from 78.46 (Mar 23) to 90.72, marking an increase of 12.26.
  • For Price / BV (X), as of Mar 24, the value is 4.96. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 23) to 4.96, marking an increase of 1.44.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.29 (Mar 23) to 4.08, marking an increase of 0.79.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ipca Laboratories Ltd as of March 12, 2025 is: ₹913.08

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Ipca Laboratories Ltd is Overvalued by 31.50% compared to the current share price 1,333.00

Intrinsic Value of Ipca Laboratories Ltd as of March 12, 2025 is: 835.10

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Ipca Laboratories Ltd is Overvalued by 37.35% compared to the current share price 1,333.00

Last 5 Year EPS CAGR: -8.54%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 16.67%, which is a positive sign.
  2. The company has higher reserves (3,737.38 cr) compared to borrowings (809.62 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (4.15 cr) and profit (384.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 111.50, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 239.08, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ipca Laboratories Ltd:
    1. Net Profit Margin: 6.86%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.44% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 8.64% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 5.61
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.3
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 46.1 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.21
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 6166.46 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals48, Kandivli Industrial Estate, Kandivli (West), Mumbai Maharashtra 400067ipca@pca.com
http://www.ipca.com
Management
NamePosition Held
Mr. Premchand GodhaExecutive Chairman
Mr. Ajit Kumar JainManaging Director
Mr. Pranay GodhaManaging Director
Mr. Prashant GodhaExecutive Director
Dr.(Mrs.) Manisha PremnathIndependent Director
Mr. Kamal Kishore SethIndependent Director
Dr. Narendra MairpadyIndependent Director
Dr.(Ms.) Swati PatankarIndependent Director
Mr. Vivek ShiralkarIndependent Director

FAQ

What is the latest intrinsic value of Ipca Laboratories Ltd?

The latest intrinsic value of Ipca Laboratories Ltd as on 12 March 2025 is ₹913.08, which is 31.50% lower than the current market price of 1,333.00, indicating the stock is overvalued by 31.50%. The intrinsic value of Ipca Laboratories Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹33,821 Cr. and recorded a high/low of ₹1,758/1,052 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹6,675 Cr and total liabilities of ₹11,424 Cr.

What is the Market Cap of Ipca Laboratories Ltd?

The Market Cap of Ipca Laboratories Ltd is 33,821 Cr..

What is the current Stock Price of Ipca Laboratories Ltd as on 12 March 2025?

The current stock price of Ipca Laboratories Ltd as on 12 March 2025 is ₹1,333.

What is the High / Low of Ipca Laboratories Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Ipca Laboratories Ltd stocks is ₹1,758/1,052.

What is the Stock P/E of Ipca Laboratories Ltd?

The Stock P/E of Ipca Laboratories Ltd is 46.1.

What is the Book Value of Ipca Laboratories Ltd?

The Book Value of Ipca Laboratories Ltd is 264.

What is the Dividend Yield of Ipca Laboratories Ltd?

The Dividend Yield of Ipca Laboratories Ltd is 0.30 %.

What is the ROCE of Ipca Laboratories Ltd?

The ROCE of Ipca Laboratories Ltd is 12.8 %.

What is the ROE of Ipca Laboratories Ltd?

The ROE of Ipca Laboratories Ltd is 9.35 %.

What is the Face Value of Ipca Laboratories Ltd?

The Face Value of Ipca Laboratories Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ipca Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE